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Abstract: Background Emotions play a critical role in our daily decisions. However, it remains unclear
how and what sort of emotional expressions are associated with therapeutic decisions in multiple sclerosis
(MS) care. Our goal was to evaluate the relationship between emotions and affective states (as captured by
muscle facial activity and emotional expressions) and TI amongst neurologists caring for MS patients when
making therapeutic decisions. Methods 38 neurologists with expertise in MS were invited to participate
in a face-to-face study across Canada. Participants answered questions regarding their clinical practice,
aversion to ambiguity, and the management of 10 simulated case-scenarios. TI was defined as lack of
treatment initiation or escalation when there was clear evidence of clinical and radiological disease activity.
We recorded facial muscle activations and their associated emotional expressions during the study, while
participants made therapeutic choices. We used a validated machine learning algorithm of the AFFDEX
software to code for facial muscle activations and a predefined mapping to emotional expressions (disgust,
fear, surprise, etc.). Mixed effects models and mediation analyses were used to evaluate the relationship
between ambiguity aversion, facial muscle activity/emotional expressions and TI measured as a binary
variable and a continuous score. Results 34 (89.4%) neurologists completed the study. The mean age
[standard deviation (SD)] was 44.6 (11.5) years; 38.3% were female and 58.8% self-identified as MS
specialists. Overall, 17 (50%) participants showed TI in at least one case-scenario and the mean (SD) TI
score was 0.74 (0.90). Nineteen (55.9%) participants had aversion to ambiguity in the financial domain.
The multivariate analysis adjusted for age, sex and MS expertise showed that aversion to ambiguity in the
financial domain (OR 1.56, 95%CI 1.32–1.86) was associated with TI. Most common muscle activations
included mouth open (23.4%), brow furrow (20.9%), brow raise (17.6%), and eye widening (13.1%). Most
common emotional expressions included fear (5.1%), disgust (3.2%), sadness (2.9%), and surprise (2.8%).
After adjustment for age, sex, and physicians’ expertise, the multivariate analysis revealed that brow
furrow (OR 1.04; 95%CI 1.003–1.09) and lip suck (OR 1.06; 95%CI 1.01–1.11) were associated with an
increase in TI prevalence, whereas upper lip raise (OR 0.30; 95%CI 0.15–0.59), and chin raise (OR 0.90;
95%CI 0.83–0.98) were associated with lower likelihood of TI. Disgust and surprise were associated with
a lower TI score (disgust: p < 0.001; surprise: p = 0.008) and lower prevalence of TI (ORdisgust: 0.14,
95%CI 0.03–0.65; ORsurprise: 0.66, 94%CI 0.47–0.92) after adjusting for covariates. The mediation
analysis showed that brow furrow was a partial mediator explaining 21.2% (95%CI 14.9%-38.9%) of the
association between aversion to ambiguity and TI score, followed by nose wrinkle 12.8% (95%CI 8.9%-
23.4%). Similarly, disgust was the single emotional expression (partial mediator) that attenuated (-13.2%,
95%CI -9.2% to -24.3%) the effect of aversion to ambiguity on TI. Conclusions TI was observed in half
of participants in at least one case-scenario. Our data suggest that facial metrics (e.g. brow furrow, nose
wrinkle) and emotional expressions (e.g. disgust) are associated with physicians’ choices and partially
mediate the effect of aversion to ambiguity on TI.
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Background: Emotions play a critical role in our daily decisions. However, it remains unclear how and what sort 
of emotional expressions are associated with therapeutic decisions in multiple sclerosis (MS) care.  
Our goal was to evaluate the relationship between emotions and affective states (as captured by muscle facial 
activity and emotional expressions) and TI amongst neurologists caring for MS patients when making therapeutic 
decisions.  
  
Methods: 38 neurologists with expertise in MS were invited to participate in a face-to-face study across Canada. 
Participants answered questions regarding their clinical practice, aversion to ambiguity, and the management of 
10 simulated case-scenarios. TI was defined as lack of treatment initiation or escalation when there was clear 
evidence of clinical and radiological disease activity.  We recorded facial muscle activations and their associated 
emotional expressions during the study, while participants made therapeutic choices. We used a validated 
machine learning algorithm of the AFFDEX software to code for facial muscle activations and a predefined 
mapping to emotional expressions (disgust, fear, surprise, etc.). Mixed effects models and mediation analyses 
were used to evaluate the relationship between ambiguity aversion, facial muscle activity/emotional 
expressions and TI measured as a binary variable and a continuous score.    
 
Results: 34 (89.4%) neurologists completed the study. The mean age [standard deviation (SD)] was 44.6 (11.5) 
years; 38.3% were female and 58.8% self-identified as MS specialists. Overall, 17 (50%) participants showed TI 
in at least one case-scenario and the mean (SD) TI score was 0.74 (0.90). Nineteen (55.9%) participants had 
aversion to ambiguity in the financial domain. The multivariate analysis adjusted for age, sex and MS expertise 
showed that aversion to ambiguity in the financial domain (OR 1.56, 95%CI 1.32-1.86) was associated with TI.  
Most common muscle activations included mouth open (23.4%), brow furrow (20.9%), brow raise (17.6%), and 
eye widening (13.1%). Most common emotional expressions included fear (5.1%), disgust (3.2%), sadness (2.9%), 
and surprise (2.8%).  After adjustment for age, sex, and physicians’ expertise, the multivariate analysis revealed 
that brow furrow (OR 1.04; 95%CI 1.003-1.09) and lip suck (OR 1.06; 95%CI 1.01-1.11) were associated with an 
increase in TI prevalence, whereas upper lip raise (OR 0.30; 95%CI 0.15-0.59), and chin raise (OR 0.90; 95%CI 
0.83-0.98) were associated with lower likelihood of TI. Disgust and surprise were associated with a lower TI score 
(disgust: p<0.001; surprise: p=0.008) and lower prevalence of TI (ORdisgust: 0.14, 95%CI 0.03-0.65; ORsurprise: 0.66, 
94%CI 0.47-0.92) after adjusting for covariates. 
The mediation analysis showed that brow furrow was a partial mediator explaining 21.2% (95%CI 14.9%-38.9%) 
of the association between aversion to ambiguity and TI score, followed by nose wrinkle 12.8% (95%CI 8.9%-





23.4%).  Similarly, disgust was the single emotional expression (partial mediator) that attenuated (-13.2%, 95%CI 
-9.2% to -24.3%) the effect of aversion to ambiguity on TI.  
 
Conclusions: TI was observed in half of participants in at least one case-scenario. Our data suggest that facial 
metrics (e.g. brow furrow, nose wrinkle) and emotional expressions (e.g. disgust) are associated with physicians’ 
choices and partially mediate the effect of aversion to ambiguity on TI.  
  






The role of emotions in decision-making has been investigated for decades. Recent studies have shown that 
emotions are the dominant driver of the majority of meaningful goal-directed decisions in life.(1, 2). Different 
emotions (fear, disgust, stress, surprise, etc.) manifested by facial muscle activation can modulate our 
perceptions and valuation of individual choices by activating different pathways involving the striatum, 
orbitofrontal cortex, the medial and dorsolateral prefrontal cortex, the inferior parietal cortex, the amygdala 
and/or insular cortex.(3-5)  
Previous studies have shown that decision making was associated with muscle activation (e.g. brow furrow, brow 
raise, lip pucker, mouth opening) and emotions (e.g. fear, sadness, anger, surprise) in consumers or healthy 
volunteers.(3, 6, 7)  For example, fear appears to be associated with pessimistic risk assessments and risk-averse 
choices, whereas anger can provoke an optimistic estimations of risk and risk-seeking behavior.(6-8) Similarly, 
some emotions, such as anger, surprise, and optimism are associated with participants’ tolerance to ambiguity 
and the selection of optimal choices.(9, 10)  However, limited information is available regarding how facial 
muscle activity (and derived emotional expressions) relate to physicians’ therapeutic decisions. 
Therapeutic inertia (TI) is a term that was introduced in 2006 to define the absence of treatment initiation or 
intensification when treatment goals are unmet.(11-13) TI is a common phenomenon affecting 50% to 90% of 
doctors caring for patients with chronic conditions (e.g. hypertension, diabetes, multiple sclerosis) and leading 
to poorer clinical outcomes and higher health care costs.(11-14)  Previous studies have identified factors 
associated with TI (15, 16), and physician factors (e.g. aversion to ambiguity) are considered the main 
contributors.(16-18). To our knowledge, there are no data showing a relationship between facial muscle 
activation, emotional expressions, and therapeutic decisions under uncertainty (or ambiguity) among practicing 
physicians. 
In this study, we evaluated facial muscle activation (and emotional expression) associated with therapeutic 
choices, particularly TI. We also sought to evaluate the mediation effect between a physical (e.g. facial muscle 





activity) or emotional (fear, disgust, surprise) response with a therapeutic decision. Given the known 
associations between specific facial muscle activation and emotional expression (anger, fear, disgust, surprise, 
etc.) with an increased attention response that precedes participants’ choices (10, 19, 20), we hypothesized that 
facial muscle activity (e.g. upper lip raise) and emotional expression (disgust, surprise) would increase 
participants’ awareness and therefore mediating the relationship between aversion to ambiguity and TI.  We 
assessed emotional expressions amongst physicians who care for people living with multiple sclerosis (MS) as 
this care model is representative of the paradigm of complex therapeutic decisions (e.g. multiple therapeutic 
options with a broad therapeutic range- e.g. different safety and efficacy profiles) in the management of a 




We conducted a cross-sectional study using the online platform Qualtrics. The study included 10 MS case-
vignettes to evaluate TI and 2 behavioural experiments to determine subject’s attitudes towards ambiguity. 
Case-scenarios were designed by our research team and MS experts (JO, GS).  Overall, 8 cases aimed to assess 
appropriate escalation of treatment (whereby an absence of treatment change corresponds to TI), while the 
remaining 2 cases were designed as controls (no indication for treatment escalation as there was no evidence 
of a clinical relapse and disease activity on brain imaging). After completing demographic information and 
questions regarding their current clinical practices, participants were exposed to behavioral experiments 
assessing ambiguity aversion and then responded to case-scenarios (Figure 1).  
Behavioural experiments were designed to assess aversion to ambiguity in the health and financial domains as 
previously reported by our group. (18, 21, 22)  Ambiguity aversion is defined as dislike for events with unknown 
probability over events with known probability.(23) For example, an ambiguity-averse individual would rather 
choose a treatment where the probability of benefits or side effects are known (even if these are somewhat 
unfavourable) over one where these probabilities are unknown. Specifically, in the health domain, participants 





were asked to choose between Treatment A (50% probability of survival) or “Treatment B” (the probability of 
survival is unknown). In the financial domain, participants were asked to choose between a visual option with 
known 50/50 probability of winning 400 or 0 US$ versus an option with unknown probability of the same 
outcomes. In both domains, we used grey bars to represent five levels (10%, 30%, 50%, 70%, and 90%) of 
unknown probability. Aversion to ambiguity was indexed in two-ways: binary (preference for the known 
probability in all 5 levels) and as continuous variable (number of levels that participants selected the known 
probability over 5).  Details of the protocol and case-scenarios were previously published.(18, 24, 25) 
 
Participants: Practicing neurologists actively involved in the care of people living with MS from across Canada 
were invited to participate in our study by the Canadian Network of MS Clinics and Neuro-sens (Neuro-
sens.com). These networks capture most of these neurologists in Canada. Participants were recruited from 
December 13, 2017 to March 2, 2018. Physicians whose practice focuses primarily on caring for MS patients 
were classified as ‘MS specialists’.  
The study was conducted in an ambulatory clinic-type setting to mimic the current clinical environment. Room 
temperature, light conditions, and participants’ sitting positions were standardized. We used a high definition 
webcam (Logitech Pro 920©) to capture facial movements. All participants had at least 90% muscle detection 
by the camera during the study period. Facial detection algorithms from AFFDEX (see below) were integrated 
with the Qualtrics survey platform through iMotions software (iMotions.com). The mean (median) duration of 
the study was 44.9 (39.9) minutes. Participants were compensated with 400 Canadian dollars. Written informed 
consent was obtained from all participants. The study was approved by the Research Ethics Board of St. Michael’s 
Hospital, University of Toronto, Canada. 
 
Assessment of emotional expressions: 
We used AFFDEX, a machine learning algorithm software that detects for emotional expressions based on facial 
muscle activity.(19, 26)  AFFDEX has been validated in more than 6 million facial videos from over 87 countries 
showing an excellent accuracy (area under the curve greater than 0.9) (https://www.affectiva.com/how/how-





it-works/, accessed Feb 28, 2019). This algorithm uses different features to identify 34 facial landmarks (e.g. eye 
corners, eye centers, nose tip, mouth corner) with a threshold area, discarding background regions (Figure 2). 
The region of interest (ROI) contains the whole face including eyes, mouth and nose. AFFDEX applies distinct 
analytical procedures to identify emotional expressions (https://developer.affectiva.com/mapping-expressions-
to-emotions/). During our study, facial detection was recorded to analyze each video frame. Eye blinking and 
closure were filtered-out.  AFFDEX uses frames with a positive detection for the subsequent analysis. 
Facial muscle activity is the main unit of study in emotional expressions. Facial movements are detected and 
mapped on probability values of emotional states (e.g. sadness, joy, disgust, anger, surprise, fear, contempt). 
The probabilities returned by the AFFDEX module range between zero and one. A value of zero indicates no 
evidence and a value of one the highest evidence that a certain emotion is fully expressed.(26)  We used raw 
values of each individual’s facial expression to directly compare amongst participants. This approach mitigates 
potential errors in the algorithms created to represent emotional expressions due to lack of matching with pre-
defined facial muscle activity.  
We use a proxy measure of participants’ arousal by combining the level of attention (a summary measure of the 
time frame each participant was looking at the screen) and engagement (a weighted sum of facial expressions). 
We compared facial muscle activity and emotional expressions between participants with and without TI. 
 
Multiple Sclerosis and Definitions: In the context of MS, TI is defined as the lack of treatment initiation or 
escalation when there is evidence of disease activity, based on clinical evidence and neuroimaging markers.(21, 
27, 28) A more proactive management strategy, including earlier use of high-efficacy DMTs and close monitoring 
of the clinical and radiological response to treatment is recommended to slow the progression of physical and 
cognitive impairments in patients with relapsing-remitting multiple sclerosis (RRMS).(29-31) Early treatment 
escalation has been shown to reduce relapse rates, disability progression, and MRI activity.(32, 33) For the 
primary analysis, we used an accepted definition of disease activity that would prompt treatment initiation or 
escalation. (27, 34, 35)  Disease activity was defined as the presence of a clinical relapse plus the presence of 





more than four new brain lesions in follow-up magnetic resonance imaging (MRI) scans or at least one 
gadolinium-enhancing lesion.(34, 35).  
TI was measured as both a continuous score and as a binary variable. The TI score corresponded to the number 
of case-scenarios where treatment initiation or escalation was warranted but not provided (numerator) divided 
by the total number of case-scenarios where TI could occur (denominator; n=8). TI as a binary variable 
(presence/absence) was determined as the lack of treatment initiation or escalation given disease activity in at 
least one case-scenario.  
 
Outcome measures: The primary outcomes of the study was the association between facial muscle activity and 
inferred emotional expression of participants at stimulus presentation (audio introducing MS case-scenarios 
under uncertainty) when making therapeutic choices and TI.  
 
Statistical analysis:  
We utilized two analytical approaches: i) a descriptive assessment of facial muscle activation and emotional 
expressions, and ii) a mediation analysis to assess how the association between aversion to ambiguity and TI 
may be mediated by facial activations and emotional expressions. Mediation analysis is a technique commonly 
used in social sciences and consumer research to make causal inferences about the influence of specific factors 
(e.g. demographic variables, participant’s characteristics, etc.) on an outcome via a third variable (called 
‘mediator’).(36, 37) A mediator is a variable that modulates the relationship between that factor with the 
outcome of interest.(36, 37)  In our analysis, the independent variable was aversion to ambiguity  and the 
dependent variable was therapeutic inertia. Facial muscle activity or an emotional expression were individually 
included as mediators.  Further details are illustrated in the appendix (Figures e1 and e2). 
The primary analysis was a descriptive assessment of the presence of facial muscle activation and emotional 
expression among participants with and without TI (binary) and by the TI score. For each screen face by 
participants, we calculated the percentage of the frames in which each facial muscle was detected relative to 





the total number of available frames as part of the AFFDEX software. Then, we identified the time period of the 
stimulus presentation and the time period of participants’ responses when making therapeutic decisions to 
specifically evaluate the association between facial muscle activation and emotional expressions during these 
two critical events. Finally, we compared the percentages of facial muscle activation and emotional expressions 
between participants with and without TI and related them to the TI score. We used a proxy measure of 
participants’ arousal defined as a summary score between attention (range 0-100) and engagement (range 0-
100).   
Specifically, we used mixed effects logistic and linear models to assess relationships between TI (and TI score) 
and the percentage of facial muscle movements (and emotional expressions) accounting for clustering (repeated 
observations on participants). The analysis was adjusted for the following explanatory variables: age, sex, 
specialist status (MS expert vs. general neurologists).  Practice setting (academic vs non-academic), percentage 
of time devoted to clinical care, and number of MS patients assessed per week had no significant impact on the 
association between emotional expressions and TI.  
We previously found an association between aversion to ambiguity and increased prevalence of TI (18). Here, 
we aimed to replicate this association and evaluated whether this observed association is mediated by facial 
muscle activation or emotional expression. For the mediation analysis we used the STATA command ‘medeff’ 
(see details of the models in the Appendix).(38, 39)  We also use structural equation modeling (SEM) to 
graphically represent the estimated mediation effects of facial metrics or emotional expressions (see details and 
interpretation of graphs in the Appendix).(40)  
In a sensitivity analysis, we considered the effect of adding participants’ number of MS patients seen per week, 
practice type (academic vs. non-academic), or years of practice instead of participants’ expertise in the 
multivariate models.  
 Goodness of fit was assessed by the c-statistic for TI (binary outcome) and R-squared for the TI score. All tests 
were 2-tailed, and p-values <0.05 were considered significant. We used STATA 13 (College Station, TX: StataCorp 
LP) to conduct all analyses. 





To facilitate the interpretation of findings, we performed the following four analyses: 
1) We evaluated the prevalence of facial muscle activations and emotional expressions; 2) We examined their 
association with the likelihood of TI and the TI score; 3) We assessed the relationship between facial metrics and 
emotional expression with ambiguity aversion (main predictor of TI in our previous studies)(18); and 4) we 
conducted a mediation analysis to determine whether facial muscle activation or emotional expression 




Of the 38 neurologists who were invited to participate in the emotional recognition study, 34 cooperated 
(cooperation rate: 89.5%) and 34 (completion rate: 100%) completed the study. The mean age (SD) of study 
participants was 44.6 (± 11.6) years; 13 participants (38.2%) were female. Twenty participants (58.8%) primarily 
focused their practice on MS care. Participants had on average 12.5 (± 12) years of experience and assessed 23.1 
(± 16) MS patients per week. Table 1 summarizes baseline characteristics of the study population.  
TI was present in 50.0% of participants in at least one case-scenario. The mean TI score was 0.74 (±0.90), and 
the range was 0 to 3. 
   
1) Prevalence of facial or emotional expressions: 
The most commonly observed muscle activations included: mouth open (23.4%), brow furrow (20.9%), brow 
raise (17.6%), and eye widening (13.1%) (Figure 2A). Brow furrow was associated with TI (p<0.001). The most 
commonly decoded emotional expressions included: fear (5.1%), disgust (3.2%), sadness (2.9%), and surprise 
(2.8%) (Figure 2C). Differences in facial muscle activation and emotional expressions by TI status are represented 
in Figure 2B and 2D. 
Participants with muscle facial activations and emotional expressions had higher arousal scores. For example, 
arousal scores were significantly higher among participants with disgust (180.7 vs. 133.1; p=0.04), surprise (77.6 





vs. 122.4; p=0.02), fear (189.9 vs 131.6; p=0.02). Similar findings were observed for facial muscle activations 
associated with TI (e.g. brow furrow [p<0.001], brow raise [p<0.001], lip suck [p<0.001], mouth open [p=0.02], 
nose wrinkle [p<0.01]).   
 
2) Basic associations between TI and facial or emotional expressions: 
The multivariate mixed effects logistic regression after adjustment for age, sex, and physicians’ expertise 
revealed that brow furrow (OR 1.04; 95%CI 1.003-1.09) and lip suck (OR 1.06; 95%CI 1.01-1.11) were associated 
with an increase in TI prevalence, whereas upper lip raise (OR 0.30; 95%CI 0.15-0.59), chin raise (OR 0.90; 95%CI 
0.83-0.98), and nose wrinkle (OR 0.08; 95%CI 0.007-0.97) were associated with lower likelihood of TI (c-statistic: 
0.889). Similar findings were obtained with linear mixed models (brow furrow: p=0.05; lip suck: p<0.001; nose 
wrinkle: p=0.017, upper lip raise: p<0.001; chin raise: p<0.001; R-squared: 0.373) where the TI score as the 
outcome of interest.   
In the emotional expression analysis, the presence of disgust (characterized by nose-wrinkle and upper lip raise) 
and surprise (characterized increased brow raise and decrease brow furrow) were associated with lower 
prevalence of TI scores (disgust: p<0.001; surprise: p=0.008) and TI (ORdisgust: 0.14, 95%CI 0.03-0.65; ORsurprise: 
0.66, 94%CI 0.47-0.92) after adjusting for age, sex and physicians’ expertise. Fear was not associated with either 
TI (ORfear: 0.37, 95%CI 0.03-5.43) or the TI score (p=0.14).  
 
3) Relation between facial and emotional expressions to ambiguity aversion: 
In our previous studies, aversion to ambiguity in the financial domain was the most relevant predictor of TI (18). 
Similarly, in the present study, 19 (55.9%) participants never chose an ambiguous alternative in the financial 
domain and 11 (32.4%) in the health domain. The multivariate analysis adjusted for age, sex and MS expertise 
showed that aversion to ambiguity in the financial (OR 1.56, 95%CI 1.32-1.86) and health (OR 1.12, 95%CI 1.02-
1.22) domains were independent predictors of TI (Table 2).  Similarly, for every 20% increase in the degree of 
ambiguity, there was a 21.5% increment (95%CI 3.0%-40.0%) in the TI score. 





 Given the consistent association between aversion to ambiguity and TI in this study and prior studies, we also 
explored the association between facial muscle activity and emotional expression and ambiguity aversion.  The 
multivariate analysis revealed that mouth opening (OR 2.10, 95%CI 1.35-3.26; p=0.001), brow furrow (OR 2.93, 
95%CI 1.84-4.65; p=<0.001), chin raise (OR 3.16, 95%CI 1.51-6.62; p=0.002), and lip suck (OR 0.38, 95%CI 0.21-
0.70; p=0.002) were the facial muscle activations associated with higher aversion to ambiguity in the financial 
domain. Disgust (OR 0.22, 95%CI 0.08-0.65; p=0.006) was the single emotional expression associated with lower 
aversion to ambiguity. 
The mixed linear regression analysis adjusted for age, sex, participants’ expertise, emotional expression (disgust) 
or facial muscle activation (brow furrow, mouth opening, and lip suck) and degree of aversion to ambiguity in 
the financial domain is presented in Figure 3. For every 20% increase in the degree of ambiguity (e.g. from 10% 
to 30%, 30% to 50% and so on), there was a 21.5% increment (95%CI 16.9%-26.0%) in the TI score (R-squared 
0.35) (Figure 3A). Nearly identical results were observed when the linear mixed model included facial muscle 
activations instead of emotional expression (R-squared 0.38) (Figure 3B). In contrast, there were no associations 
between facial muscle activation and emotional expression with aversion to ambiguity in the health domain.  
 
4) Mediation analysis: facial and emotional expressions modulate the relationship between aversion to 
ambiguity and TI 
We found that brow furrow followed by nose wrinkle were the strongest mediators, respectively explaining 
21.2% (95%CI 14.9%-38.9%) and 12.8% (95%CI 8.9%-23.4%) of the effect of aversion to ambiguity in the financial 
domain on TI (Figures 4A and 4B). Similarly, disgust was the single emotional expression that attenuated (-13.2%, 
95%CI -9.2% to -24.3%) the effect of aversion to ambiguity in the financial domain on TI (Figure 4C).  
Notably, the direct effect of ambiguity aversion on TI was greater than the indirect effect mediated by brow 
furrow, nose wrinkle, or disgust (partial mediators). For example, there was a significant, but modest increment 
(<5%) in the R-square values when adding the facial or emotional variable into the mixed models. This is also 





reflected in the larger β coefficients for the direct effect between ambiguity aversion and TI compared to the 
multiplication of β coefficients for the indirect effect (Figure 4 and figure e2).  
Other facial muscle activations (e.g. lip suck: p-value 0.84) and emotional expressions had a non-significant or a 
negligible effect (e.g. surprise and fear <3%). The sensitivity analysis revealed no changes in the β coefficients 
for ambiguity aversion when adjusting mixed models for other covariates (see appendix, figures e3 and e4). 
 
DISCUSSION:  
The influence of emotions on the therapeutic decisions of physicians is an important but largely unexplored field. 
In the present study, we analyzed facial muscle activations and emotional expressions among neurologists while 
they were making therapeutic decisions. By using the paradigm of complex therapeutic decisions in MS care, we 
found that emotional expressions (e.g. disgust and surprise) were associated with lower TI. We also observed 
that facial components of emotional expressions were also associated with TI. Specifically, brow furrow, lip suck 
and nose wrinkle were associated with an increased prevalence of TI, whereas upper lip raise, and chin raise 
were associated with a lower likelihood of TI. We also found that aversion to ambiguity increased the likelihood 
of TI. Participants with the aforementioned emotional expressions and muscle facial activations had higher 
arousal scores compared to those without.  
The mediation analysis revealed that disgust was the single emotion that attenuated the effect of aversion to 
ambiguity in the financial domain on TI. Similarly, the assessment of component processes that mapped to 
emotional expressions revealed that brow furrow and nose wrinkle were the strongest facial factors explaining 
21% and 13% of the influence of aversion to ambiguity on TI.   
 
What is the relevance of our findings for clinical practice? 
TI is a common phenomenon affecting 50% to 90% of physicians who manage patients with chronic medical 
conditions (e.g. hypertension, diabetes, chronic obstructive pulmonary disease, multiple sclerosis, among 
others).(15, 41-44).  TI has been associated with poorer patient outcomes and higher health care costs due to  





the lack of appropriate treatment escalation (affecting one out of six clinical encounters) leading to higher 
hospitalizations, greater disability, and lower productivity.(14, 18, 24, 45)  It may occur with insufficient 
knowledge integration and knowledge-to-action gaps as a result of automatic responses leading to suboptimal 
therapeutic decisions. Specifically, neurologists caring for MS patients sometimes fail to integrate presented 
information (e.g. MS severity, relapses within the last three years, imaging findings with the risk of disease 
progression) with best practice recommendations.(46-49) In the present study, we found an association 
between facial and emotional expressions with aversion to ambiguity and TI.  
 
Prior studies have demonstrated that interventions increasing physicians’ arousal or awareness (e.g. through 
warning and categorization strategies) were associated with more accurate diagnostic or therapeutic 
decisions.(50, 51) A recent randomized clinical trial showed that neurologists who received the traffic light 
system educational intervention had a 70% reduction in TI (manuscript submitted for publication in Feb 2019). 
Furthermore, several studies demonstrated a link between specific emotions (e.g. disgust) increasing attention 
at early stages of visual processing.(52) These prior findings, together with observations from the current study 
suggest that emotional expressions  and strategies that enhance participants awareness (via increasing attention 
or arousal) may reduce TI. 
Furthermore, our findings of (i) brow furrow being associated with both increased TI and ambiguity aversion and 
(ii) disgust being associated with both reduced TI and lower ambiguity aversion indicates that common 
emotional factors may contribute to both behaviors. In our previous studies, aversion to ambiguity was the most 
significant physician-level factor associated with TI.(16, 18, 53)  Given the limited training in risk management 
and formal learning in medical decisions, physicians are clearly vulnerable when handling decisions under 
uncertainty, especially when having aversion to ambiguity.(54-56)  Taken together, these findings suggest that 
interventions reducing TI may partly rely on emotional factors (51) and that emotional factors may play a more 
important role for medical decision making than hitherto assumed. 
 





What brain pathways that may underpin the link between emotions and TI? 
Previous studies suggest that the neural mechanisms mediating the relation between affect and decisions 
depend on a participant’s emotional arousal and engagement with the specific choice to be made. (3) For 
example, disgust has been associated with the activation of the insular cortex which may lead to increased 
arousal modulating the neural responses to aversion to ambiguity, which results in influencing subsequent 
decision-making.(57, 58)  Disgust was also shown to increase arousal by modulating emotion-specific 
attention.(52)  This finding is also consistent with an increased arousal score associated with disgust (and its 
muscle components) in our study.    
 
Traditionally, the striatum, the amygdala, the medial prefrontal, orbitofrontal and insular cortices are thought 
to process emotional aspects of the decision-making process.(3, 7) Moreover, the dorsolateral and anterior 
prefrontal cortices and the posterior parietal cortex may modulate cognitive aspects of decisions.(4) Previous 
studies showed that stress reduces activity in dorsolateral and orbital parts of prefrontal cortex while it enhances 
amygdala activity, leading to decreased goal-directed behavior and increased emotional responses (e.g. fear, 
disgust, contempt).(59, 60)  Findings from our study are in keeping with this proposed framework as they support 
an association between facial metrics and emotional expressions (disgust) which may increase participant’s 
awareness/arousal (reflected by increased arousal scores) regarding a compelling decision, thereby showing a 
reduction in ambiguity aversion and lowering the likelihood of TI (Figure 5).  We could speculate that muscle 
activations associated with disgust and surprise may reflect increased activity of the insular cortex and amygdala 
leading to greater arousal and lower TI. Further studies using time-resolved neural methods are needed to test 
this hypothesis.  
 
Limitations 
Our study has a number of significant limitations. First, although we used a validated software to detect facial 
muscle activation, the association with emotional expressions may require further assessment. Second, there is 





a high variability of emotional expressions when participants are exposed to a specific stimulus. As such, our 
results should be interpreted with caution considering there are no other similar studies available for 
comparison. Third, the sample size is small affecting the precision of our results (e.g. wider confidence intervals). 
Fourth, the prevalence of emotional expressions was relatively low likely due to: i) the strict pre-specified 
correlation mapping used by AFFDEX software (that combines the concomitant activation of several facial 
muscles to code for a single emotion)(19), and ii) emotions are inherently social, and therefore more neutral 
expressions are commonly observed when participants are exposed to computer-based simulated scenarios.(61, 
62)  Finally, our stimulus was based on case-scenarios that may not truly reflect the therapeutic decisions in 
clinical practice.  
Despite these limitations, our study is the first to show that facial muscle activations and emotional expressions 
are associated with therapeutic decisions made by physicians who care for MS patients.   
 
Conclusions 
This information helps improve our understanding of the influence of emotional expressions on physicians’ 
therapeutic decisions. These findings, in conjunction with results from a prior study that demonstrated the 
benefits of an educational intervention on reducing TI have practical clinical implications. With further studies, 
it may be possible to identify physicians at high risk of having TI by evaluating physical, emotional, and behavioral 
responses (aversion to ambiguity) and tailor educational interventions to these individuals.  Identifying and 
administering appropriate educational interventions in such situations may facilitate optimal therapeutic 
decisions in chronic diseases, resulting in better patient outcomes and lower health care costs.    
  





Figure legends:  
Figure 1: Study design and facial landmarks  
(A) Sequence of study events. After answering demographic and practice-based questions and determining 
medical and financial ambiguity aversion, participants listened to a case-scenario and then viewed 6 therapeutic 
choices. This procedure was repeated for each of the 10 case-scenarios ranging from 25 to 50 seconds. All the 
stimuli remained on the screen until the participant selected one of the therapeutic choices. Then, the 
participant was able to see the next screen and play the next case-scenario. The dots between the screen 
presenting the therapeutic choices #1 and the case-scenario #10 represent the progression through scenarios 
#2-#9. (B) Facial landmarks. The region of interest in AFFDEX software contains the whole face including eyes, 
mouth and nose. Each of the 34 facial landmarks are the main unit of study to represent 20 facial expression 
metrics that are mapped to represent emotional expressions (https://developer.affectiva.com/mapping-
expressions-to-emotions/). This figure illustrates the representation of the data at a particular time-point of the 
study, including: facial metrics, screens of the stimulus presentation, and time landmarks according to the study 
design and flow. A value of zero indicates no evidence and a value of one the highest evidence that a certain 
facial metric or emotion is fully expressed. (23)  
  
Figure 2. Facial muscle activations overall and in relation to TI status.  
(A) Overall proportion of facial muscle activations in ascending order. Values at the top of the bars represent the 
proportion of muscle activation during the study period. (B) Represents the distribution of facial muscle 
activations as shown in (A) stratified by responses with (red) and without (blue) TI. Values within bars represent 
the proportion of muscle activations by TI status. For example, brow furrow activation was observed in 19.1% of 
responses, 14.7% among participants with TI and the remaining 4.4% among participants without TI.  The x-axis 
represents individual facial metric as identified by the AFFDEX software for activations greater than 1%. (C) 
Overall proportion of emotional expressions in ascending order. Values at the top of the bars represent the 
proportion of emotional expressions during the study period. (D) Represents the distribution of emotional 
expressions as shown in (C) stratified by responses with (red) and without (blue) TI. For example, disgust was 
observed in 8% of responses, 5.8% among participants without TI and the remaining 2.2% among participants 
with TI. The x-axes represent each individual emotional expression as mapped by the AFFDEX software.  
* indicates p-values <0.01, ** indicates p-values <0.001, † indicates p-values <0.05->0.01 for differences 
between participants with and without TI.  
 
 





Figure 3. Predicted TI score as a function of degrees of aversion to ambiguity  
The mixed linear regression models were adjusted for age, sex, participants’ expertise (MS expert vs. general 
neurologist), disgust (panel A) or facial muscle activation (brow furrow, mouth opening, and lip suck) (Panel B). 
The gray are represents the 95%CI of the predicted TI score. 
For the model accounting for emotional expression (disgust) (Panel A), the R-squared of 0.35 represents the 
proportion of the variability of the TI score explained by the model. For every 20% increase in the degree of 
aversion to ambiguity (e.g. from 10% to 30% or from 50% to 90%), there was a 21.5% increment in the TI score.  
For the model accounting for facial muscle activations (Panel B), the R-squared of 0.38 represents the proportion 
of the variability of the TI score explained by the model. For every 20% increase in the degree of aversion to 
ambiguity (e.g. from 10% to 30% or from 50% to 90%), there was a 19.5% increment in the TI score. The gray are 
represents the 95%CI of the predicted TI score. 
 
Figure 4. Mediation analysis: graphs derived from structural equation models with a single mediator (see also 
explanatory figure e1 in the appendix)  
(A) Structural equation model graph for the modulation of brow furrow (mediator) on the relationship between 
aversion to ambiguity (independent variable) and therapeutic inertia score (outcome). The R-squared for the 
model was 0.38. (B) Structural equation model graph for the modulation of nose wrinkle (mediator) on the 
relationship between aversion to ambiguity (independent variable) and therapeutic inertia score (outcome). The 
R-squared for the model was 0.34. (C) Structural equation model graph for the modulation of disgust (mediator) 
on the relationship between aversion to ambiguity (independent variable) and therapeutic inertia score 
(outcome). The R-squared for the model was 0.35 Age, sex and MS expertise were included as covariates. Values 
next to the arrows represent β coefficients,  represent the variance of the mediator and outcome of interest 
(TI score).  Values within each square box represent the mean (upper values) and variance (lower value) of each 
variable included in the models.  
* represents a p-value <0.001, † represents a p-value <0.05 and >0.01 for the total effect models.  
 
Figure 5. Schematic representation of factors associated with therapeutic inertia (TI)  
There is a direct effect of ambiguity aversion and TI and an indirect effect of facial muscle activations (e.g. brow 
furrow, lip suck) and emotional expressions (e.g. disgust) modulating the relationship between ambiguity 
aversion and therapeutic inertia. Demographic and practice factors (e.g. number of MS patients seen per week) 
may also contribute to TI.    
 
 





 Table 1. Baseline characteristics of participants 
Characteristics  Total (%) 
n=34 
Age (mean ± SD), in years 44.6 ± 11.6 
Age ≥ 50 years 13 (38.2) 
Sex 
  Female 13 (38.2) 
Specialty 
  MS specialists 20 (58.8) 
  General Neurologists who care for MS patients 14 (41.2) 
Practice Setting 
  Academic 28 (82.4) 
 Community 6 (17.6) 
% time in clinical practice 
 
50-74% of their time 16 (47.2) 
Greater than 75% 15 (44.1) 
Years in practice (mean ± SD) 12.5 ±11.8 
MS patients seen per week (mean ± SD) 23.1 ± 15.8 
Author of a peer-reviewed publication in the last 12 months 22 (64.7) 
Numbers in brackets indicate percentages 
  





Table 2. Relationship between aversion to ambiguity and therapeutic inertia 
 N of individual 
responses 








 n individual responses 
among participants 
with aversion to 
ambiguity /total 






Aversion to Ambiguity 
(Financial domain) 
380/680 (55.9) 0.21 (0.16-0.26) 1.56 (1.32-1.86) 0.82 
Aversion to Ambiguity 
(Health domain) 
460/680 (66.7) 0.06 (0.03-0.08) 1.12 (1.02-1.22) 0.78 
 
* Mixed linear regression models for TI score (dependent variable) adjusted for age, sex, MS expert and aversion to 
ambiguity (independent variables)  
 
† Mixed logistic regression models for TI (dependent variable) adjusted for age, sex, MS expert and aversion to ambiguity 
(independent variables).  
  















Figure 2. (A) Prevalence of facial muscle activations  
 
Figure 2. (B) Prevalence of facial muscle activations by TI status 
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(C) Prevalence of emotional expressions overall 
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Figure 3. Predicted TI score by degrees of aversion to ambiguity score  
 
Panel A: Accounting for the effect of emotional expression (disgust) 
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Figure 4. Graphs derived from the structural equation modelling representing the mediation analysis (see 
also explanatory figure in the appendix)  
 
Panel A. Direct, indirect, and total effect of aversion to ambiguity on TI with brow furrow as mediator 
 
 
Panel B. Direct, indirect, and total effect of aversion to ambiguity on TI with nose wrinkle as mediator 
 
 





















































































Figure 5. Proposed pathways associated with Therapeutic Inertia: integration of demographic, physical, 
emotional, and behavioral mechanisms  
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Mediation Analysis:  
The mediation analysis characterizes the relationship between the independent variable (X; ambiguity 
aversion) and variables that are related with an outcome of interest (Y; TI). A mediating variable (M; 
facial muscle activation or emotional expression) is hypothesized to be intermediate in the relation 
between an independent variable (X) and an outcome (Y) 
 




The mediation model decomposes the total effect of X on Y (c), into two parts: the indirect effect of X 
on Y, quantified by ab (the product of a and b), and the direct effect of X on Y with the effect of the 
mediator removed, quantified by c′; where X= aversion to ambiguity, Y= therapeutic inertia (TI) and 
M= facial muscle activation or emotional expression. 
  












The sensitivity analysis revealed no significant differences in the direction of the effect or relationship 
between ambiguity aversion and TI. For example, the inclusion of years of practice in the adjustment 
(instead of MS expertise) revealed that the total mediated effect of brow furrow was 8.6% (95%CI 5.2%-
24.6%). Similarly, the total direct effects of disgust was -8.3% (95%CI -5.0% to -22.7%). Figures e3 and 
e4 (appendix) showed the minimal changes in the β coefficients for the direct effect of aversion to 
ambiguity compared to figure 4. There was a minimal increment (<3%) to the R-square value (R-square: 
0.34) when adding a facial or emotional variable into the mixed models with adjustment for years of 
practice instead of participants’ expertise in MS care. Similar findings were observed when including 






























Figure e3: Graphs representing the relationships between ambiguity aversion and the TI score 
in the sensitivity analysis with brow furrow as the mediator.  
 
 
 Figure e4: Graphs representing the relationships between ambiguity aversion and the TI score 
in the sensitivity analysis with disgust as the mediator.  
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